Antihyperglycemic-Sod/Gluc Cotransport-2 (SGLT2) Inhibitors

Antihyperglycemic sodium-glucose cotransporter-2 (SGLT2) inhibitors are a therapeutic class of oral medications that regulate systemic glucose levels by selectively inhibiting SGLT2 proteins in the proximal renal tubules By blocking the reabsorption of filtered glucose and sodium, these agents promote urinary glucose excretion and osmotic diuresis

Antihyperglycemic sodium-glucose cotransporter-2 (SGLT2) inhibitors are a therapeutic class of oral medications that regulate systemic glucose levels by selectively inhibiting SGLT2 proteins in the proximal renal tubules Originally developed to improve glycemic control in patients with type 2 diabetes mellitus, members of this class also provide significant cardio-renal protective benefits Consequently, they are widely indicated to reduce the risk of cardiovascular events, manage heart failure a...

Antihyperglycemic sodium-glucose cotransporter-2 (SGLT2) inhibitors are a therapeutic class of oral medications that regulate systemic glucose levels by selectively inhibiting SGLT2 proteins in the proximal renal tubules By blocking the reabsorption of filtered glucose and sodium, these agents promote urinary glucose excretion and osmotic diuresis

By blocking the reabsorption of filtered glucose and sodium, these agents promote urinary glucose excretion and osmotic diuresis Consequently, they are widely indicated to reduce the risk of cardiovascular events, manage heart failure across various ejection fraction spectrums, and slow disease progression in patients with chronic kidney disease

Originally developed to improve glycemic control in patients with type 2 diabetes mellitus, members of this class also provide significant cardio-renal protective benefits